Search
for

    Research

    5 / 1000+ results

      research Primary cicatricial alopecias: clinicopathology of 112 cases

      254 citations , December 2003 in “Journal of the American Academy of Dermatology”
      This study reviewed the epidemiology and treatment of inflammatory cicatricial alopecias and highlighted the importance of scalp biopsies for accurate diagnosis in a mixed ethnic population at a university hair clinic.
      The Pathogenesis of Primary Cicatricial Alopecias

      research The Pathogenesis of Primary Cicatricial Alopecias

      150 citations , October 2010 in “The American Journal of Pathology”
      This review discusses the pathogenesis and challenges in treating primary cicatricial alopecia, highlighting the need to understand immune protection collapse in hair follicle stem cells; it reports no new clinical results.
      Management of Primary Cicatricial Alopecias: Options for Treatment

      research Management of primary cicatricial alopecias: options for treatment

      98 citations , May 2008 in “British Journal of Dermatology”
      This review discusses evidence-based guidance for managing primary cicatricial alopecias but reports no new clinical results, highlighting significant gaps in knowledge and the need for more quality trials.
      Primary Cicatricial Alopecia: Treatment Approaches and Classification

      research Primary cicatricial alopecia

      95 citations , November 2016 in “Journal of The American Academy of Dermatology”
      This article reviews primary cicatricial alopecias, focusing on lymphocytic forms such as chronic cutaneous lupus erythematosus, according to a classification by the North American Hair Research Society, and reports no new clinical results.

    Community Join

    2 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.